New Zealanders Can Now Access Funded OPDIVO® (Nivolumab) For Previously Treated Metastatic Renal Cell Carcinoma
Bristol Myers Squibb is delighted to announce that OPDIVO® (nivolumab) is now funded for metastatic clear cell renal cell carcinoma (RCC) patients with disease progression following previous anti-angiogenic therapy.[1]
2 Nov 18:33 · SCOOP